J. Pers. Med. 2012, 2(1), 15-34; doi:10.3390/jpm2010015
Opinion

Trends in Personalized Therapies in Oncology: The (Venture) Capitalist’s Perspective

* email and email
Received: 9 February 2012; in revised form: 22 February 2012 / Accepted: 29 February 2012 / Published: 7 March 2012
(This article belongs to the Special Issue Recent Advances in Personalized Medicine)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Oncology is one of the most important fields of personalized medicine as a majority of efforts in this field have recently centered on targeted cancer drug development. New tools are continuously being developed that promise to make cancer treatment more efficacious while causing fewer side effects. Like most industries, the biopharmaceutical industry is also following certain global trends and these are analyzed in this article. As academia and industry are mutually dependent on each other, researchers in the field should be aware of those trends and the immediate consequences for their research. It is important for the future of this field that there is a healthy relationship among all interested parties as the challenges of personalized medicine are becoming ever more complex.
Keywords: global industry trends; collaboration BioPharma–Academia; oncology drug development; translational research
PDF Full-text Download PDF Full-Text [323 KB, uploaded 7 March 2012 12:21 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Fleck, R.; Bach, D. Trends in Personalized Therapies in Oncology: The (Venture) Capitalist’s Perspective. J. Pers. Med. 2012, 2, 15-34.

AMA Style

Fleck R, Bach D. Trends in Personalized Therapies in Oncology: The (Venture) Capitalist’s Perspective. Journal of Personalized Medicine. 2012; 2(1):15-34.

Chicago/Turabian Style

Fleck, Roman; Bach, Daniel. 2012. "Trends in Personalized Therapies in Oncology: The (Venture) Capitalist’s Perspective." J. Pers. Med. 2, no. 1: 15-34.

J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert